Your browser doesn't support javascript.
loading
Potential Role of Inflammation-Promoting Biliary Microbiome in Primary Sclerosing Cholangitis and Cholangiocarcinoma.
Miyabe, Katsuyuki; Chandrasekhara, Vinay; Wongjarupong, Nicha; Chen, Jun; Yang, Lu; Johnson, Stephen; Chia, Nicholas; Walther-Antonio, Marina; Yao, Janet Z; Harrington, Sean C; Nordyke, Cynthia K; Eaton, John E; Gossard, Andrea A; Oli, Sharad; Ali, Hamdi A; Lavu, Sravanthi; Giama, Nasra H; Hassan, Fatima A; Ali, Hawa M; Enders, Felicity T; Ilyas, Sumera I; Gores, Gregory J; Topazian, Mark D; Kashyap, Purna C; Roberts, Lewis R.
Afiliación
  • Miyabe K; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
  • Chandrasekhara V; Department of Gastroenterology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya 466-8650, Japan.
  • Wongjarupong N; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
  • Chen J; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
  • Yang L; Division of Computational Biology, Mayo Clinic, Rochester, MN 55905, USA.
  • Johnson S; Microbiome Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA.
  • Chia N; Division of Computational Biology, Mayo Clinic, Rochester, MN 55905, USA.
  • Walther-Antonio M; Microbiome Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA.
  • Yao JZ; Division of Computational Biology, Mayo Clinic, Rochester, MN 55905, USA.
  • Harrington SC; Microbiome Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA.
  • Nordyke CK; Division of Computational Biology, Mayo Clinic, Rochester, MN 55905, USA.
  • Eaton JE; Microbiome Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA.
  • Gossard AA; Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA.
  • Oli S; Microbiome Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA.
  • Ali HA; Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA.
  • Lavu S; Department of Obstetrics & Gynecology, Mayo Clinic, Rochester, MN 55905, USA.
  • Giama NH; Microbiome Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA.
  • Hassan FA; Microbiome Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN 55905, USA.
  • Ali HM; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
  • Enders FT; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
  • Ilyas SI; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
  • Gores GJ; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
  • Topazian MD; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
  • Kashyap PC; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.
  • Roberts LR; Department of Pathology, Westchester Medical Center, Valhalla, NY 10595, USA.
Cancers (Basel) ; 14(9)2022 Apr 24.
Article en En | MEDLINE | ID: mdl-35565248
ABSTRACT

BACKGROUND:

Primary sclerosing cholangitis (PSC) is a major risk factor for cholangiocarcinoma (CCA). We investigated biliary and fecal microbiota to determine whether specific microbes in the bile or stool are associated with PSC or CCA.

METHODS:

Bile was obtained from 32 patients with PSC, 23 with CCA with PSC, 26 with CCA without PSC, and 17 controls. Over 90% of bile samples were from patients with perihilar CCA. Stool was obtained from 31 patients with PSC (11 were matched to bile), 16 with CCA with PSC (10 matched to bile), and 11 with CCA without PSC (6 matched to bile). Microbiota composition was assessed using 16SrRNA-marker-based sequencing and was compared between groups.

RESULTS:

Bile has a unique microbiota distinguished from negative DNA controls and stool. Increased species richness and abundance of Fusobacteria correlated with duration of PSC and characterized the biliary microbiota in CCA. Stool microbiota composition showed no significant differences between groups.

CONCLUSIONS:

We identified a unique microbial signature in the bile of patients with increased duration of PSC or with CCA, suggesting a role for microbiota-driven inflammation in the pathogenesis and or progression to perihilar CCA. Further studies are needed to test this hypothesis.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
...